Download
Platform overview
Genesis Therapeutics is an AI-driven drug discovery platform built to shorten the timeline for bringing new medicines from concept to candidate. By applying advanced molecular artificial intelligence, the company searches for previously uncharacterized protein targets and probes underexplored regions of chemical space to identify promising therapeutic molecules.
Core capabilities
- High-fidelity molecular simulations that improve insight into how compounds behave and interact.
- 3D spatial graph models that represent molecular structure and relationships in three dimensions.
- Algorithms for discovering novel protein targets and generating candidate chemistries across unconventional chemical space.
People and collaborations
The platform is supported by a multidisciplinary team that blends domain knowledge and engineering:
- Software engineers who build and maintain the computational infrastructure.
- Deep learning researchers developing the models that predict molecular properties.
- Experienced drug hunters bringing biochemical and translational expertise.
Strategic industry relationships underline the platform’s credibility and reach:
- Roche
- Genentech
- Eli Lilly
Funding and market position
Genesis Therapeutics has attracted significant investment, including a recent $200 million Series B financing, which reinforces its position among leading AI-first drug discovery companies. That capital has allowed the organization to scale its research, expand partnerships, and accelerate candidate generation.
Suggested alternative for market insight
For teams seeking a free tool focused on competitive and market intelligence (rather than molecular design), consider SEMrush’s free tier as a resource for tracking visibility, keywords, and competitive landscape.
Technical
- Web App
- Full
